Ranbaxy Board Approves Spin-off Of Drug Discovery Company
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian firm reports $1.2 billion in sales for the first nine months of 2007.
You may also be interested in...
Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb
Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.
Ranbaxy/GSK Partnership Yields First Drug Candidate
Ranbaxy will develop a respiratory disease candidate through proof of concept under an expanded discovery agreement inked with GSK in February.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.